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Abstract The clinical course of renal cell carcinoma 
(RCC) is highly variable. Overexpression f the p53 pro- 
tein has been suggested as a possible prognostic parame- 
ter in RCC. Overexpression f the mdm-2 oncogene prod- 
uct has been shown to interact with the p53 function. To 
investigate the immunohistochemical overexpression of
mdm-2 protein in comparison with that of p53 protein in 
RCC, 50 nonpapillary pT3 RCCs were immunostained for 
p53 protein (DO-7) and mdm-2 (IF2). Tumor growth frac- 
tion (Ki-67 labeling index; MIB-1) was determined by im- 
munohistochemistry, p53 positivity was detected in 16% 
of tumors, mdm-2 overexpression was seen in 30% of 
RCCs. There was a significant association between p53 
and mdm-2 immunostaining (P = 0.0006), suggesting that 
mdm-2 protein may contribute to p53 protein stabilization 
in RCC. p53 overexpression was associated with a high 
Ki-67 LI (P = 0.0002), suggesting that p53 overexpression 
is involved in growth control in RCC. Survival analysis 
showed that Ki-67 LI (P=0.04) and p53 overexpression 
were as sociated with poor prognosis (P = 0.0021), whereas 
mdm-2 overexpression was not related to patient outcome 
(P--- 0.73). A Cox regression analysis revealed tumor stage 
(P<0.001) and p53 overexpression (P<0.05) to be inde- 
pendent prognostic parameters. It is concluded that p53 but 
not mdm-2 may be of practical relevance in predicting pa- 
tient prognosis in RCC. 
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Introduction 
Renal cell carcinoma (RCC) accounts for an estimated 
20000 new cases/year in the United States [1]. Five-year 
survival is about 45% in tumors extending beyond the re- 
nal capsule (pT3). The outcome of patients with pT3 tu- 
mors cannot be satisfactorily predicted in individual pa- 
tients. Better knowledge of the individual prognosis would 
be an aid in selecting patients for adjuvant treatment mo- 
dalities. 
The p53 protein is a product of the most commonly mu- 
tated gene in human tumors characterized to date. Muta- 
tions of the p53 gene can result in an increased half-life of 
the p53 protein, making it detectable by immunohisto- 
chemistry [2]. However, immunohistochemical p53 over- 
expression can also be caused by nonmutational mecha- 
nisms, and not all mutations result in p53 overexpression 
[3]. Recent studies have suggested that p53 overexpression 
is associated with poor prognosis and with sarcomatoid 
transformation i  RCC [4, 5]. 
Recently, an endogenous gene product has been identi- 
fied that can bind to p53 protein and affect its function: 
the mdm-2 (murine double minute-2) protein [6, 7]. The 
mdm-2 oncogene on chromosome 12q13-14 encodes anu- 
clear phosphoprotein that may interact with both mutant 
and wild-type p53 proteins [7]. The mdm-2 gene product 
can inhibit p53-mediated transactivation, and it has been 
suggested that p53 and mdm-2 reciprocally regulate ach 
other [6, 7]. The mdm-2 gene has been found to be dereg- 
ulated in human sarcomas, gliomas, breast carcinomas, and 
leukemias [8-10]. 
In this study we have used immunohistochemistry to in- 
vestigate the frequency of mdm-2 protein overexpression 
in comparison to that of p53 protein overexpression in a 
series of 50 consecutive pT3 nonpapillary RCCs. To study 
the biological significance of these parameters, p53 and 
mdm-2 overexpression were correlated with Ki-67 label- 
ing index (LI) and patient prognosis. 
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Materials and methods 
Patients and tumor samples 
Tumor samples of 50 consecutive, previously untreated nonpapillary 
RCCs extending beyond the renal capsule (pT3) were formalin fixed 
and paraffin embedded. Four-micrometer sections were used for 
hematoxylin and eosin (H & E) staining and immunostaining. His- 
tologic lassification was performed as described by Weiss et al. [ 11 ]. 
The tumors were graded according to the Thoenes grading system 
[ 12] and staged according to the UICC classification [ 13]. Metastat- 
ic status at the time of surgery was determined from patient charts. 
Follow-up and overall survival data of all patients were obtained 
from the attending physicians. 
Immunohistochemistry 
Formalin-fixed tumors were immunostained forp53 and mdm-2 pro- 
tein. Proliferative activity was assessed by detecting the Ki-67 pro- 
tein. All immunohistochemical examinations were performed using 
the avidin-biotin-enhanced immunoperoxidase technique as recent- 
ly described [14]. A microwave/citrate buffer procedure was em- 
ployed to improve antigen retrieval as described [ 14]. Negative con- 
trol slides were prepared by omitting the primary antibody. 
Sections of the paraffin samples were immunostained formdm-2 
protein using the IF-2 monoclonal ntibody (IF2; 1:20, Calbiochem, 
Cambridge, MA). IF2 recognizes an epitope in the amino-terminal 
portion of the human mdm-2 protein. Positive controls for mdm-2 
consisted of metastatic melanoma with known positivity. 
The anti-p53 antibody (DO-7, 1:400, Dako, Glostrup, Denmark) 
was used to detect p53 immunoreactivity as previously described 
[ 14-16]. The anti-p53 antibody DO-7 reacts with wild-type and mu- 
tant p53 protein. Positive controls for p53 consisted of breast cancer 
with known positivity. Only nuclear immunoreactivity forthe above 
antibodies were scored as positive. The fraction of cells showing nu- 
clear p53 and mdm-2 positivity was estimated in all cases. 
The monoclonal ntibody MIB 1 (1:800; Dianova, Hamburg, Ger- 
many) was used to detect the Ki-67 antigen. The Ki-67 antigen rep- 
resents a nuclear cell proliferation-associated protein expressed in
G1, S, G2, and M phases of cell cycle, but not in nonproliferative 
GO cells [17]. Reading of the stained sections was done without 
knowledge of the clinical data. Ki67 labeling indices (percentage of 
positive cells, LI) were determined by scoring 300 tumor cells in tu- 
mor areas with the highest density of Ki-67-positive cells. Nuclei 
were considered Ki-67 positive if any nuclear staining was seen. On- 
ly nuclear staining was considered. The median percentage ofposi- 
tive cells was used as a cutoff point to define groups with low and 
high proliferative activity. 
Statistics 
Contingency table analysis was used to examine the relationship be- 
tween p53 immunostaining, mdm-2 immunostaining, tumor grade, 
and stage. Student's t-test was employed to examine the relationships 
among both p53 and mdm-2 with Ki-67 labeling index (LI). Life ta- 
bles were estimated by the Kaplan-Meier statistic and survival curves 
were compared by a log-rank test. Surviving patients were censored 
at the date of their last clinical control. Cox regression analysis was 
used to test for independent prognostic significance. 
dian 7 cm, range 3.5-15 cm). Thirty-one tumors were non- 
metastatic (pT3 NO, cM0) and 19 metastatic (pT3, pN 1, or 
cM1) at the time of diagnosis. Tumor size and histologic 
grade were not associated with metastatic disease at pres- 
entation (data not shown). The median fol low-up period 
for the patients was 37 months (range 2-108 months). 
Thirty-two patients died during the fol low-up period. Al l  
of the patients who died had metastatic disease at their last 
cl inical control. 
Mdm-2 
Mdm-2 staining was always nuclear (Fig. 1). No immuno- 
reactivity was found in normal renal parenchymal  cells, 
stromol cells, or lymphoid cells. In tumors, nuclear mdm- 
2 overexpression was always heterogeneous, with a few 
scattered mdm-2-posi t ive cells within the tumor. Mdm-2-  
posit ive cells never represented more than 10% of the tu- 
mor cells. Mdm-2-posi t ive nuclei were identif ied in 15 of 
50 pT3 RCC cases (30%) studied. There was no associa- 
tion between mdm-2 posit ivity and tumor diameter, tumor 
grade, or stage (Table 1). Mdm-2 posit ivity was not asso- 
ciated with patient prognosis (Fig. 2). 
p53 
A nuclear p53 overexpression was observed in 8 of 50 
(16%) cases. The p53 immunoreact iv i ty was confined to 
tumor cell nuclei. A weak p53 cytoplasmic posit ivity was 
seen in a few cases. Cytoplasmic posit ivity was considered 
negative. Tumors did not stain homogeneously.  No case 
contained more than 10% immunoreact ive tumor cells. 
p53 overexpression was not related to tumor diameter, tu- 
mor grade, or metastasis (Table 1). Comparison of p53 
overexpression with patient prognosis revealed a signifi- 
cantly better prognosis for p53-negative than for p53-pos- 
itive tumors (P= 0.00021; Fig. 3). 
Results 
Clinicopathologic data of patients 
Twenty-seven tumors were grade 2 and 23 tumors were 
grade 3. The mean tumor diameter was 7.7 + 2.7 cm (me- 
Fig. 1 Immunostaining of mdm-2. Renal cell carcinoma showing 
nuclear staining, x560 
Table 1 p53/mdm-2 overex- 
pression and tumor phenotype 
in pT3 RCC 
Number p53 
positive a 
(%) 
P value* Number mdm-2 
positive a 
(%) 
Tumor diameter _<7 cm 17 3 (18) 
>7 cm 33 5 (15) 
Tumor grade b G2 27 2 (8) 
G3 23 6 (26) 
Metastasis NO, M0 31 3 (10) 
N1 or M1 19 5 (26) 
0.86 
0.18 
0.25 
7 (41) 
8 (24) 
9 (35) 
6 (26) 
8 (26) 
7 (37) 
* Chi-square test 
Defined for positivity; see text 
b According to Thoenes grading system 
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Fig. 2 Overall survival of patients with pT3 RCC according to p53 
overexpression 
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Fig. 3 Overall survival rates of patients with pT3 RCC according 
to mdm-2 overexpression 
p53 positivity was strongly associated with mdm-2 
overexpression. Seven out of 8 p53-positive tumors were 
mdm-2 positive, but only 8 of 42 p53-negative tumors 
(P= 0.0006). 
Table 2 Ki-67 LI and tumor phenotype 
n Ki-67 LI P value* 
Tumor grade a G2 27 6.0 _+ 5.3 
G3 22 11.7 _+ 10.6 0.0184 
Metastasis NO, M0 30 7.1 + 8.4 
N1 orM1 19 10.9-+8.5 0.1389 
p53 b Negative 41 6.7 -+ 6.7 
Positive 8 18.3 _ 10.5 0.0002 
mdm-2 b Negative 35 6.4 _+ 7.2 
Positive 15 13.6 _+ 9.4 0.0049 
* Student's t-test 
a According to Thoenes grading system 
b Defined for positivity; see text 
Table 3 p53, mdm-2, and Ki67 LI 
n Ki-67 LI (%) P value* 
mdm-2 negative 35 6.4_+7.2 0.0001 a
mdm-2 positive/p53 negative 8 7.3_+4.7 0.0017 a
mdm-2 positive/p53 positive 7 20.8+8.3 
* Student's t-test 
a Versus mdm-2 positive/p53 positive 
Tumor growth fraction (Ki-67 LI) 
Forty-nine tumors stained successfully for Ki-67. One tu- 
mor showed Ki-67-negative mitoses and a total lack of 
Ki-67-positive cells. This tumor was excluded from Ki-67 
analysis. The mean Ki-67 LI was 8.4_8.6% (range 
0.1-32.4%, median 6%), while normal renal tissue had 
Ki-67 LIs fewer than 2%. There was a significant relation- 
ship between Ki-67 LI and histologic grade (P = 0.02), but 
Ki-67 LI was not related to presence of metastases (Table 
2). 
Both p53 (P=0.0002) and mdm-2 (P=0.005) were as- 
sociated with rapid tumor cell proliferation in univariate 
analysis (Table 2). However, the combined analysis of p53 
and mdm-2 revealed that this was driven by p53 positivity 
(Table 3). 
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Table 4 Cox regression a alysis 
Relative risk P 
Metastases 4.41 0.0001 
p53 3.00 0.0275 
Grade 1.21 0.5291 
Ki-67 1.11 0.7561 
Multiparameter analysis 
Cox regression analysis including the variables metastatic 
disease, histologic grade, p53 positivity, and Ki-67 LI 
showed that only metastatic tumor disease and p53 over- 
expression were independent prognostic factors, the rela- 
tive risk of progression being 4.41 (P<0.0001) and 3.0 
(P-0.0275), respectively. Histologic tumor grade and 
Ki-67 LI provided no additional prognostic information 
(Table 4). 
Discussion 
Tumor stage and tumor grade are regarded as the major 
pathomorphologic prognostic factors of survival in RCC 
[12, 18, 19]. The biological relevance of p53 immuno- 
reactivity in RCC [4, 20] is controversial. In this set of 
patients with identical tumor stage and histologic tumor 
type, p53 overexpression by immunohistochemistry was
sig-nificantly associated with patient survival, while his- 
tologic grade and tumor size yielded no prognostic infor- 
mation. 
In this study, immunohistochemistry was used to deter- 
mine p53 overexpression. A nuclear p53 overexpression 
was found in 16% of 50 nonpapillary pT3 RCCs. This is 
similar to the rate found in several other studies (range from 
11% to 33%) [4, 21-23]. Overexpression f the p53 pro- 
tein is often caused by missense mutations of thep53 gene, 
since p53 gene mutations lead to stabilization of the pro- 
tein which can then be detected by immunohistochemis- 
try. However, several previous tudies have shown that mu- 
tations of the p53 tumor suppressor gene are either signif- 
icantly less frequent than in other tumors [24, 25] or are 
totally absent in RCC [23]. Therefore, alternative pathways 
may have caused p53 stabilization i RCC. 
p53 stabilization may also be achieved through binding 
to other cellular proteins, such as the mdm-2 oncoprotein 
as shown in sarcomas [6, 10]. The significant association 
of p53 and mdm-2 in our study suggests an interaction be- 
tween these proteins and raises the possibility that mdm-2 
overexpression contributes to p53 protein stabilization i
RCC. This could be important inthe pathogenesis of these 
cases, since mdm-2 may deregulate the p53-dependent 
growth-suppressive pathway [7]. It has been shown that u- 
mor cells can tolerate levels of wild-type p53 that are nor- 
mally growth-suppressive if they overexpress the mdm-2 
gene [261. 
Several mechanisms have been described to induce 
mdm-2 overexpression i cluding mdm-2 amplification, 
RNA overexpression, or post-translational stabilization. 
The mdm-2 gene is amplified in a significant percentage 
of human sarcomas [27]. In a recent study by Imai et al. 
[25], no amplification of the mdm-2 gene was detected 
by dot-blot analysis in 49 renal tumors, suggesting that 
mdm-2 amplification is at least a rare mechanism for 
mdm-2 overexpression in RCC. The general absence of 
mdm-2 amplification is also consistent with our previous 
observation showing a lack of any amplifications in a 
different set of 42 RCCs by comparative genomic hybrid- 
ization [28]. Therefore, the high percentage of mdm-2 
immunopositivity (30%) suggests that mdm-2 overex- 
pression in RCC could be due to other mechanisms than 
gene amplifications, uch as chromosomal translocations 
or mutations which could increase the level of mdm-2 pro- 
tein. 
mdm-2 immunohistochemical re ctivity in the absence 
of mdm-2 gene amplification has been reported in soft tis- 
sue sarcomas [29] and on breast carcinomas [30]. Marchetti 
et al. [30] showed that breast cancer cases with high-level 
mdm-2 amplifiction had a high percentage (>_10%) of cells 
with mdm-2 overexpression. I  contrast, cases with bor- 
derline mdm-2 amplifications ortumors with mdm-2 over- 
expression i the absence of amplification showed a per- 
centage of mdm-2-immunoreactive cellsranging from 0.1 
to 5 %. Our finding that in all mdm-2-immunopositive cas s 
the number of immunoreactive tumor cells was low (<10% 
of tumor cells) is consistent with an overexpression f
mdm-2 in the absence of high-level gene amplification i
RCC. mdm-2 protein immunoreactivity was not observed 
in normal epithelial and stromal cells, similar to most other 
normal tissue examined for mdm-2 [31]. mdm-2 immuno- 
reactivity in normal tissue was only reported by Wiethege 
et al. [32] in bronchial epithelial cells. 
A number of previous tudies using flow cytometry, mi- 
totic index, proliferating-cell nuclear antigen (PCNA), and 
Ki-67 immunohistochemistry [33-37] have suggested a 
prognostic mportance oftumor cell proliferation i RCC. 
Previous tudies have examined the relationship between 
p53 overexpression a d tumor proliferation i  a variety 
of tumors including breast, colon, prostate, and lung. 
Most reports howed an increased tumor proliferation i  
p53-positive tumors. In the present study a correlation be- 
tween p53 immunostaining and Ki-67 LI was observed, 
providing additional evidence that p53 alterations, al- 
though rare in RCC, confer a highly aggressive phenotype 
to these tumors. The association between ahigh Ki-67 LI 
and mdm-2 positivity in our study could suggest hat 
mdm-2 overexpression is also involved in promoting RCC 
tumor cell proliferation. However, the combined analysis 
of both p53 and mdm-2 overexpression showed that this 
was driven by p53 overexpression alone. A possible xpla- 
nation is that mdm-2 overexpression alone is not sufficient 
to increase tumor aggressiveness. Although p53 overex- 
pression was associated with mdm-2 overexpression, the 
lack of an association between mdm-2 overexpression a d 
patient prognosis further indicates that immunohistochem- 
ical detection of mdm-2 is of l ittle practical relevance in 
RCC. 
Altered p53 overexpression has been suggested to pre- 
dict adverse prognosis in RCC [4], although these f indings 
have not been consistently conf irmed [21, 22]. The analy- 
sis of our cl inical data showed that p53 overexpression a d 
Ki-67 LI  were signif icantly associated with prognosis if 
uniparameter analysis was performed. Mult iparameter 
analysis by the Cox hazard model  showed that only pres- 
ence of metastases and p53 overexpression were indepen- 
dent predictors of tumor progression, whereas histologic 
grade, Ki-67 LI, and mdm-2 overexpression provided no 
addit ional prognostic information. This f inding empha- 
sizes the potential prognostic usefulness of p53 immuno- 
histochemistry in RCC. 
In summary, this study shows that p53 is associated with 
tumor progression in pT3 RCC. The associat ion between 
p53 and mdm-2 overexpression suggests that mdm-2 pro- 
tein overexpression may be involved in the regulation of 
the p53 protein function in RCC. mdm-2 overexpression 
without p53 protein overexpression is not associated with 
tumor cell prol i feration and mdm-2 overexpression offers 
no prognostic information in patients treated by nephrec- 
tomy. 
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